

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b

Aksana Vasilyeva¹, Selvi Durmus², Lie Li¹, Els Wagenaar², Shuiying Hu¹, Alice A. Gibson¹, John C. Panetta¹, Sridhar Mani³, Alex Sparreboom¹, Sharyn D. Baker¹, and Alfred H. Schinkel²

Abstract

Recently, an efficient liver detoxification process dubbed "hepatocyte hopping" was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by

Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as "hepatocyte hopping"—a novel concept in clinical pharmacology—for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib. *Cancer Res*; 75(13): 2729–36. ©2015 AACR.

Introduction

Sorafenib is a multikinase inhibitor that is approved for treatment of advanced thyroid (1), renal cell (2), and hepatocellular carcinomas (3), and is being evaluated for treatment of acute myeloid leukemia (4) and ovarian cancer (5). Like other orally administered tyrosine kinase inhibitors, sorafenib displays wide interindividual pharmacokinetic variability, which can significantly affect drug-induced toxicity and possibly efficacy (6, 7). Although the metabolic pathways of sorafenib have been reasonably well established, involving a CYP3A4-mediated route to form sorafenib-N-oxide (8) and a UGT1A9-mediated route to form sorafenib-glucuronide (SG; ref. 9), the primary causes of the pharmacokinetic variability remain unknown (10, 11). It has been suggested that sorafenib undergoes enterohepatic recirculation, a process that involves removal of solutes from blood by uptake into hepatocytes, excretion into bile, and intestinal reabsorption, sometimes accompanied by hepatic conjugation and

intestinal deconjugation (12). However, the occurrence of enterohepatic recirculation of sorafenib has not been experimentally demonstrated but was inferred from *in vitro* biliary clearance studies in sandwich-cultured human hepatocytes (13), and provides a means to explain observed time profiles of sorafenib levels in plasma of cancer patients (14).

We recently reported that mice lacking 1A- and 1B-type organic anion-transporting polypeptides (Oatp1a/1b), uptake transporters localized to the sinusoidal (basolateral) membrane of hepatocytes, experience substantially increased plasma levels of SG after oral sorafenib administration (15). This phenomenon resembles our earlier findings with conjugated bilirubin (16, 17), whereby Oatp1a/1b-deficiency leads to excessive buildup of bilirubin-glucuronide (BG) in the systemic circulation, which can ultimately result in jaundice. In the case of bilirubin, Oatp1a/1b transporters work in concert with the basolaterally located efflux transporter Abcc3 (Mrp3) to mediate hepatic efflux and subsequent reuptake of BG into hepatocytes, a phenomenon we called "hepatocyte hopping" (16, 18). This process is operational not only under pathologic, but also normal physiologic conditions, and results in a substantial amount of hepatocytic BG not being secreted into bile by Abcc2 (Mrp2), but transported back into the blood by Abcc3. These molecules are then taken up again in adjacent downstream hepatocytes by Oatp1a/1b, affording another chance of being secreted into bile. This liver-to-blood shuttling loop allows management of situations where biliary secretion in upstream hepatocytes is saturated, for example due to substrate overload or incidental inhibition (18). With this process, BG can be safely eliminated, instead of becoming trapped inside upstream hepatocytes. Thus, a more evenly distributed biliary secretion of substrates over the entire liver

¹Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. ²Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ³Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

A. Vasilyeva and S. Durmus contributed equally to this article.

Corresponding Author: Sharyn D. Baker, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, MS 314, TN 38105. Phone: 901-595-3089; Fax: 901-595-3125; E-mail: sharyn.baker@stjude.org

doi: 10.1158/0008-5472.CAN-15-0280

©2015 American Association for Cancer Research.

lobule can be achieved, leading to an efficient hepatic detoxification. Although demonstrated so far only for one endogenous solute, based on the broad substrate specificity of the transporters involved (19), it is possible that many xenobiotics and their glucuronide conjugates are subject to the same hepatocyte hopping process.

In this study, we aimed to understand the processes underlying sorafenib glucuronide hepatocyte shuttling, biliary excretion, and intestinal recycling using *in vitro* and *in vivo* models, and thus to elucidate mechanisms contributing to sorafenib interindividual pharmacokinetic variability.

Materials and Methods

In vitro vesicular transport

Vesicles from Sf9 cells (Life Technologies) expressing mouse Abcc2 (mAbcc2), rat Abcc2 (rAbcc2), human ABCC2 (ABCC2), human ABCC3 (ABCC3), or human ABCC4 (ABCC4) were incubated with sorafenib (10 $\mu\text{mol/L}$; Chemie Tek) or SG (10 $\mu\text{mol/L}$) for 5 minutes in the presence or absence of ATP (4 mmol/L) or rifampin (100 $\mu\text{mol/L}$), then lysed with 0.1 mol/L HCl, and analyzed by liquid chromatography-tandem mass spectrometry (LC/MS-MS; ref. 20). ATP-dependent transport of sorafenib and SG was determined by subtracting AMP-dependent transport from ATP-dependent transport, with both expressed in pmol/min/mg, after normalization for nonspecific transport observed in control vesicles. Uptake experiments were carried out at a concentration of 10 $\mu\text{mol/L}$, which is equivalent to average sorafenib plasma steady-state concentrations achievable in adults and children treated at 400 mg or 200 mg/m² twice daily (9, 21).

Animals

Abcc4^{-/-} mice on a C57BL/6 background were generated and bred in-house at St. Jude Children's Research Hospital (Memphis, TN), and Abcc2^{-/-} mice on an FVB background were provided by Taconic. All other knockout strains on an FVB background were generated and bred in-house at The Netherlands Cancer Institute (Amsterdam, the Netherlands). Real-time PCR analyses demonstrated that the expression of relevant drug transporters did not substantially change in any of these knockout strains (Supplementary Table S1). Therefore, the possibility of major compensatory changes in transporter expression affecting the interpretation of results was ruled out. Abcc2^{-/-} rats on a Sprague-Dawley background were obtained from Sage Labs. Mice and rats were housed in a temperature-controlled environment with a 12-hour light cycle and given a standard diet and water *ad libitum*. Experiments were approved by the Institutional Animal Care and Use Committees of St. Jude Children's Research Hospital and the Netherlands Cancer Institute.

Plasma pharmacokinetic studies

Murine studies were performed as described previously (15). Briefly, mice were fasted for 3 hours prior to administration of sorafenib (10 mg/kg; formulated in 50% Cremophor EL and 50% ethanol, then diluted 1:4 with deionized water) by oral gavage. A sorafenib dose of 10 mg/kg in FVB wild-type mice achieves sorafenib plasma steady-state concentrations ranging from approximately 6 to 10 $\mu\text{mol/L}$, similar to that achieved in humans. Serial blood samples were taken from individual mice at 0.25, 0.5, and 1 hour from the submandibular vein, at 2 and 4

hours from the retro-orbital sinus, and at 7.5 hours by a terminal cardiac puncture (Abcc2^{-/-} and Abcc4^{-/-} mice); or by tail vein sampling at 0.25, 0.5, 1, 2, and 4 hours and at 8 hours by a terminal cardiac puncture (all other knockout strains). In Oatp1a/1b^{-/-} mice and all other double- and triple-knockout mice, serial tail vein blood samples were obtained at 0.25, 0.5, 1, and 2 hours (~peak concentration) after drug administration, and livers were obtained at the last time point. To evaluate the role of enterohepatic cycling in sorafenib disposition, FVB wild-type mice received neomycin (200 mg/kg; diluted in saline) by oral gavage, every 12 hours for 5 days. On the last day, mice received SG (10 mg/kg diluted in water) immediately after the last neomycin dose. In an initial study, serial blood samples were taken from individual mice at 0.25, 1, 2, 4, 8, and 24 hours after SG administration, and sorafenib was not detected in plasma until 8 hours after SG administration. In a follow-up study, SG was administered and serial blood samples were obtained at 8 (submandibular vein), 12, and 16 hours (retro-orbital sinus), and at 24 hours (cardiac puncture). For studies with rats, animals were fasted overnight before administration of sorafenib (10 mg/kg), and serial blood samples were taken at 0.5 and 1.5 hours (retro-orbital plexus), 4 and 8 hours (saphenous vein), 12 hours (tail vein), and 24 hours (cardiac puncture). All blood samples were centrifuged at 3,000 \times g for 5 minutes, and tissues were homogenized in 10 volumes (*w/v*) of water and stored at -80°C until analysis. Sorafenib and SG pharmacokinetic parameters in all mouse strains were calculated using noncompartmental techniques via WinNonlin 6.3 (Pharsight). In addition, sorafenib plasma concentration-time data from wild-type and Abcc2^{-/-} mice were analyzed simultaneously using population pharmacokinetic modeling via Monolix version 4.3.3. (22). A one-compartment model with first-order oral absorption was used to model the data. A covariate (wild-type vs. knockout mouse) on a single parameter was considered significant if the -2 Log-Likelihood was decreased by at least 3.84 units ($P < 0.05$).

Urinary excretion studies

Mice were placed into metabolic cages at least 3 days prior to the start of the study and were kept on reverse 12-hour light cycle, with free access to a standard diet and water *ad libitum*. After mice received a single dose of sorafenib (10 mg/kg) by oral gavage, serial blood samples were taken at 4.5, 24, 48, and 72 hours and plasma was isolated by centrifugation. Urine was collected for 72 hours after sorafenib administration. Plasma, urine, and liver concentrations of sorafenib, sorafenib-N-oxide, and SG were determined by LC/MS-MS.

Bile collection


Bile duct cannulation/catheterization was done as described previously (23), except that animals remained under isoflurane anesthesia during the surgery and bile collection. For studies in mice, bile collection was started 30 minutes after oral sorafenib administration and continued for 2 hours. In rats, bile collection was started 2 hours and 25 minutes after oral sorafenib administration and continued for 2 hours, using 15-minute fractions.

Ex vivo microsomal incubations

Mouse liver and intestinal microsomes were prepared as described previously (24, 25), and rat liver microsomes were purchased from Sigma-Aldrich. Incubations were performed as described previously (9).

Figure 1.

Transport of sorafenib and SG by ABC transporters. Transport of sorafenib (10 $\mu\text{mol/L}$; A) or SG (10 $\mu\text{mol/L}$; B) in transporter-expressing inside-out vesicles using a 5-minute incubation period in the presence or absence of ATP (4 mmol/L) or rifampin (rif; 100 $\mu\text{mol/L}$). Mouse and rat transporters are designated by the prefix "m" or "r," respectively. The human transporters are shown in capitals. Data represent the mean \pm SE of difference between ATP- and AMP-dependent transport (both expressed in pmol/min/mg) after normalization for nonspecific transport observed in control vesicles, from three to four independent experiments (3–18 replicates). Asterisks above bars indicate significant differences in uptake between vesicles expressing the indicated transporter and control vesicles. *, $P < 0.05$; ****, $P < 0.0001$. Square brackets, *, $P, 0.05$ and ****, $P < 0.0005$ for differences in uptake by ABCC2, ABCC3, or ABCC4 with or without rifampin. ABCC2- (C), ABCC3- (D), or ABCC4- (E) expressing or control vesicles were incubated with increasing concentrations of SG for 5 minutes in the presence of ATP (4 mmol/L).



Ex vivo cecal incubations

Cecal contents were extracted from euthanized mice, divided into equal parts, and immediately placed into 4-mL thioglycollate media. In select experiments, enzymatic activity was terminated by heat (65°C) pretreatment for 30 minutes. Incubations were initiated by addition of SG (2 $\mu\text{mol/L}$), and formation of sorafenib was assessed in serial 50- μL aliquots obtained at 0, 0.25, 0.5, 1, 3, and 6 hours.

Statistical analysis

All data shown are mean \pm SE. Statistical analyses were done using GraphPad Prism 5.0. All tests were two-tailed t tests, and $P < 0.05$ was considered statistically significant.

Results and Discussion

Identification of SG as a substrate of ABCC2, ABCC3, and ABCC4

In order to identify efflux proteins involved in the transport of sorafenib and SG in hepatocytes, experiments were initially carried out using inside-out vesicles expressing various transporters of the ABC family. Following a 5-minute incubation period, sorafenib uptake was moderately increased by human ABCC2, but not by ABCC3, ABCC4, or mouse Abcc2 (Fig. 1A). Rat Abcc2 may also transport sorafenib, albeit weakly. The modest transport of sorafenib by human ABCC2 is consistent with an earlier report demonstrating that overexpression of ABCC2 results in resistance to sorafenib-induced cell growth inhibition (26).

Unlike for sorafenib, uptake of SG was efficiently increased relative to control vesicles by each transporter tested (Fig. 1B). ABCC2-, ABCC3-, and ABCC4-mediated uptake was sensitive to

inhibition by rifampin (Fig. 1B), a known inhibitor of ABC (27). The transport of SG by human ABCC2 was saturable with a Michaelis–Menten constant (K_m) of 22 ± 6.6 $\mu\text{mol/L}$ and a maximal velocity (V_{max}) of 155 ± 11 pmol/min/mg, corresponding to a value for transport efficiency (V_{max}/K_m) of 7.0 (Fig. 1C). The transport of SG by ABCC3 (K_m , 186 ± 72 $\mu\text{mol/L}$; V_{max} , 196 ± 44 pmol/min/mg) and ABCC4 (K_m , 146 ± 14 $\mu\text{mol/L}$; V_{max} , 221 ± 11 pmol/min/mg) was also saturable (Fig. 2D and E), but the transport efficiency was about 7-fold lower than that observed for ABCC2.

ABCC2 mediates biliary excretion of SG

The *in vivo* role of ABCC2 in the transport of sorafenib and SG was next evaluated in Abcc2-deficient (Abcc2^{-/-}) mice receiving oral sorafenib (Supplementary Table S2). Compared with wild-type mice, Abcc2-deficiency was not associated with altered plasma disposition of sorafenib (Fig. 2A), liver uptake (Fig. 2B and Supplementary Fig. S1A), or biliary output (Fig. 2C and Supplementary Fig. S1C). In contrast, plasma levels of SG after sorafenib administration were increased by approximately 350-fold in Abcc2^{-/-} mice (Fig. 2D), and accompanied by a decreased liver-to-plasma ratio, and approximately 3-fold increase in liver concentrations (Fig. 2E and Supplementary Fig. S1B). These changes were not due to increased hepatic or intestinal biotransformation of sorafenib (Supplementary Fig. S2A and S2B) or shunted urinary excretion, which was found to be a minor route of elimination irrespective of Abcc2 status (Supplementary Fig. S2C and S2D). Consistent with the known localization of Abcc2 on the bile canalicular membrane (28), we found that the biliary output of SG was reduced by approximately 12-fold in Abcc2^{-/-} mice




Figure 2. Pharmacokinetics of sorafenib and SG in wild-type and *Abcc2*^{-/-} mice. Plasma concentration-time profiles (A and D) and liver-to-plasma ratio (B and E) of sorafenib and SG, respectively, in female wild-type and *Abcc2*^{-/-} mice. Sorafenib was administered orally at a dose of 10 mg/kg. Livers were taken at 2 and 7.5 hours after sorafenib administration (*n* = 4 per group). Concentrations in liver (*C_L*) were normalized to corresponding concentrations in plasma (*C_P*). C and F, bile-to-plasma concentration ratios of sorafenib and SG, respectively, in wild-type and *Abcc2*^{-/-} mice. Sorafenib (10 mg/kg) was administered orally 30 minutes before the start of bile collection (*N* = 3 wild-type; *N* = 2 *Abcc2*^{-/-} mice). Bile was collected for 2 hours. Data represent the mean ± SE.

(Fig. 2F and Supplementary Fig. S1D), despite an approximately 3-fold higher liver concentration. These findings suggest that under *Abcc2*-proficient conditions, SG is effectively secreted into bile and its appearance in the systemic circulation represents an overshoot mechanism that poorly reflects the extent of its formation (29).

To determine whether these phenotypes are also observed in another species, sorafenib pharmacokinetics were assessed in wild-type and *Abcc2*^{-/-} rats. *Abcc2*-deficiency in rats resulted in an approximately 2-fold increase in plasma levels of both sorafenib (Fig. 3A) and sorafenib-N-oxide (Fig. 3B). Unexpectedly, however, SG was not detected in plasma or bile of either wild-type or *Abcc2*^{-/-} rats (Fig. 3C). *Ex vivo* metabolism studies indicated that, compared with mice and humans (9), rat liver microsomes lack a significant capacity to form SG (Fig. 3D). These results indicate that the rat is an inadequate model for the human pharmacokinetics of sorafenib. Moreover, the involvement of *ABCC2* in the transport of unchanged sorafenib may become increasingly important when glucuronidation is defective, a possibility that is consistent with recent clinical data (10). Collectively, the data indicate that biliary excretion of SG is primarily mediated by *ABCC2* and therefore is an important determinant of SG pharmacokinetics.

Oatp1a/1b and *Abcc3* transporters cooperatively transport SG *in vivo*

The disposition of sorafenib was next evaluated in wild-type, *Oatp1a/1b*^{-/-}, *Abcc3*^{-/-}, and *Oatp1a/1b;Abcc3*^{-/-} mice. Plasma levels of sorafenib were not substantially altered in any of the strains (Supplementary Fig. S3A), and liver levels of sorafenib were also similar between knockout and wild-type strains (Supplementary Fig. S3B), although plasma sorafenib exposure was approximately 25% lower in *Oatp1a/1b*^{-/-} mice, similar to our previous observations (15). These findings indicate that the


differences between the strains were marginal for plasma and liver levels of sorafenib, and unlikely to directly confound the interpretation of SG levels.

As shown previously (15), the impact of *Oatp1a/1b* transporters on the disposition of SG was far higher than that for sorafenib, and absence of the *Oatp1a/1b* transporters resulted in an approximately 60-fold increase in the plasma levels of SG (Fig. 4A and Supplementary Table S2). Importantly, this increase was partially reversed (by ~2-fold) in *Oatp1a/1b;Abcc3*^{-/-} mice, suggesting that *Abcc3* activity contributes to the increased plasma levels of SG. In contrast, *Abcc3* deficiency alone did not lead to altered plasma SG levels, indicating that the impact of *Abcc3* does not come to the fore in the presence of *Oatp1a/1b* transporters (Fig. 4A). Similar results were obtained in a separate experiment terminated at 2 hours (i.e., around the peak plasma levels of SG), showing 125- and 56-fold increased plasma levels in *Oatp1a/1b*^{-/-} and *Oatp1a/1b;Abcc3*^{-/-} mice compared with wild-type mice, respectively (Supplementary Table S3). In liver samples, there was only a slight increase in SG levels in both *Oatp1a/1b*^{-/-} and *Oatp1a/1b;Abcc3*^{-/-} mice compared with the wild-type strain (Fig. 4B), and an accordingly large decrease in liver-to-plasma ratio (Fig. 4C). As might be expected, in both *Abcc3*-deficient strains, liver-to-plasma ratios of SG were somewhat increased relative to their *Abcc3*-proficient counterparts (Fig. 4C). These data suggest a major role of *Oatp1a/1b* transporters in hepatic (re-)uptake of SG and a clear impact of *Abcc3* on sinusoidal extrusion of SG. The role of *Abcc3* as a hepatic basolateral efflux transporter of SG is consistent with the previous observation that SG can be extruded into the medium of sandwich-cultured hepatocytes exposed to sorafenib (13), and with its partial recovery in urine of patients treated with sorafenib (29).

Because the present results indicate the presence of another efflux transporter located at the sinusoidal membrane of

Figure 3.

Pharmacokinetics of sorafenib in wild-type and *Abcc2*^{-/-} rats. Plasma concentration-time profiles of sorafenib (A) and sorafenib-N-oxide (B) in wild-type and *Abcc2*^{-/-} rats after oral administration of sorafenib at 10 mg/kg (*n* = 8/group). SG concentrations were below the limit of quantitation (BLQ). Data represent the mean ± SE. C, biliary excretion of sorafenib and SG in wild-type and *Abcc2*^{-/-} rats. Sorafenib (10 mg/kg) was administered orally 2 hours 25 minutes before bile collection (*n* = 2/group). Bile was collected in 15-minute fractions for 45 minutes. The results show collection at 2 hours 40 minutes after sorafenib administration (from 2 hours 25 minutes to 2 hours 40 minutes after sorafenib). D, *ex vivo* metabolism of sorafenib in liver microsomes of wild-type (WT) mice and rats. Liver microsomes (1 mg/mL) were incubated with 10 μmol/L sorafenib for 60 minutes. Data represent the mean ± SE from one to two independent experiments (3–6 replicates). BLQ, below the analytic assay limit of SG quantitation (<0.26 pmol/min/mg).



hepatocytes that can mostly compensate for the loss of *Abcc3*, we next evaluated whether *Abcc4* could be this partially redundant transporter. Using *Abcc4*^{-/-} and *Abcc3;Abcc4*^{-/-} mice, we found that concentrations of SG in plasma and liver were not substantially affected by *Abcc4* deficiency, whereas *Abcc3*^{-/-} and *Abcc3;Abcc4*^{-/-} mice did show increased SG liver-to-plasma concentration ratios compared with both other strains (Supplementary Fig. S4 and Supplementary Table S3). Similar observations were made for single *Abcc4* deficiency in another mouse strain, C57BL/6 (Supplementary Table S2). The data indicate that *Abcc4* deficiency, unlike *Abcc3* deficiency, does not have a noticeable impact on the sinusoidal efflux of SG *in vivo*. The effective expression of mouse *Abcc4* in the sinusoidal membrane may be too low to exert much effect. Moreover, the modest effect of the *Abcc3* deficiency in reducing plasma SG levels in *Oatp1a/1b;Abcc3*^{-/-} and in *Oatp1a/1b;Abcc2;Abcc3*^{-/-} mice (Fig. 4A and D) suggests that there are one or more other sinusoidal SG efflux mechanisms of unknown identity, which may provide about similar SG efflux activity as the sinusoidal *Abcc3*.

Sinusoidal transport of SG is affected by *Abcc2* and *Abcc3* deficiency

The disposition of sorafenib was then evaluated in *Oatp1a/1b;Abcc2*^{-/-} and *Oatp1a/1b;Abcc2;Abcc3*^{-/-} mice. In line with our findings in the single *Abcc2*^{-/-} mice, we found that deletion of *Abcc2* in combination with deletion of *Oatp1a/1b* led to a very large increase in plasma exposure of SG compared with wild-type

mice (909-fold), but also compared with *Oatp1a/1b*^{-/-} mice (12.7-fold; Fig. 4D; Supplementary Table S2). At 2 hours, the liver levels of SG were 1.8-fold higher in the *Oatp1a/1b;Abcc2*^{-/-} mice compared with wild-type mice (Fig. 4E). As a result of the highly increased plasma levels of SG, liver-to-plasma ratios decreased in all transporter knockout mice compared with wild-type mice (Fig. 4F). These findings support an important role for *Abcc2* in the biliary excretion of SG, and that deletion of *Abcc2* in addition to *Oatp1a/1b* deficiency leads to a major increase in the sinusoidal extrusion of this metabolite back into the circulation.

We found that SG plasma exposure was reduced by 30% in *Oatp1a/1b;Abcc2;Abcc3*^{-/-} mice compared with *Oatp1a/1b;Abcc2*^{-/-} mice (Fig. 4D). The impact of *Abcc3* in liver remained noticeable with a 1.5-fold increase in absolute levels of SG in liver (Fig. 4E) and a 1.7-fold increase in the liver-to-plasma ratios (Fig. 4F) at 2 hours in *Oatp1a/1b;Abcc2;Abcc3*^{-/-} mice compared with *Oatp1a/1b;Abcc2*^{-/-} mice. Plasma and liver levels of sorafenib were not substantially altered in these strains (Supplementary Fig. S3C and S3D). Collectively, these findings indicate that *Abcc3* has a clear impact on sinusoidal secretion of SG, and in combination with the previously demonstrated ability of *Oatp1a/1b* to take up SG across the sinusoidal membrane, can result in "hepatocyte hopping" of this drug conjugate. However, there are other partially redundant sinusoidal efflux transporters for SG that limit the absolute impact of *Abcc3* deficiency in mice, perhaps especially at the high hepatocyte SG levels caused by the impaired biliary excretion via *Abcc2*.




Figure 4. Pharmacokinetics of SG in wild-type, Abcc3^{-/-} mice, Oatp1a/1b^{-/-}, and combination Abcc2^{-/-} and Abcc3^{-/-} mice. Concentration-time profiles of SG in plasma (A and D), liver (B and E), and liver-to-plasma ratios (C and F) in wild-type and transporter knockout mice. Sorafenib 10 mg/kg was administered orally ($n \geq 4$ /group). Data represent the mean \pm SE. Asterisks indicate a significant difference in SG liver concentrations and liver to plasma concentration ratios between transporter knockout and wild-type mice. *, $P < 0.05$; **, $P < 0.005$.

SG deconjugation by mouse intestinal β -glucuronidases

In order to assess the fate of SG secreted by Abcc2 into bile, we next performed *ex vivo* incubation studies of mouse intestinal (cecal) content based on the consideration that once in the intestines, SG may serve as a substrate for bacterial β -glucuronidase enzymes that are produced by bacteria normally inhabiting the intestines (30). The removal of the glucuronide group in SG by β -glucuronidase generates a carbon source for the bacteria and, in the process, SG is reactivated back to the pharmacologically active sorafenib. Over a 6-hour period in a crude suspension of cecal content, we observed a time-dependent decrease in SG levels and a corresponding increase in sorafenib (Fig. 5A). Heat-pretreatment of the cecal samples at 65°C resulted in abrogation of sorafenib formation, indicating that the deconjugation of SG is an enzyme-mediated process. Furthermore, we found that the formation of sorafenib from SG was reduced by approximately 3-fold in cecal samples from mice that had been pretreated with neomycin to eliminate the intestinal flora (Fig. 5B; ref. 31). This finding is consistent with the conjecture that

β -glucuronidases produced by intestinal microbiota are responsible for the deconjugation of SG to sorafenib.

To demonstrate that sorafenib can be generated from SG *in vivo*, wild-type mice received neomycin or vehicle for 5 days followed by oral administration of a single dose of SG. In an initial study, highly variable peak SG concentrations (15.4–3788 ng/mL) were observed at 15 minutes with rapid elimination within 1 to 2 hours, but sorafenib was not detected in plasma until 8 hours after SG administration. In a repeat study, blood was collected more frequently between 8 and 24 hours. Whereas sorafenib levels in plasma of neomycin-pretreated mice were below the limit of quantification, significant levels of sorafenib in plasma were observed in vehicle-pretreated mice, with a delay in peak levels (226–897 ng/mL) at 8 hours after SG administration (Fig. 5C). The substantial delay in availability of sorafenib from SG deconjugated in the small intestine of mice suggests that an 8-hour sample collection period is too short to observe effects of strongly altered SG disposition in transporter-deficient mice on parent




Figure 5. Sorafenib formation from SG by mouse intestinal contents. A and B, formation of sorafenib upon *ex vivo* incubation of FVB mouse cecal contents with SG (2 μ mol/L) with or without heat pretreatment (65°C; A), or after treatment of mice with saline or oral neomycin 200 mg/kg given twice daily for 5 days ($n \geq 4$ /group; B). Data were normalized to SG concentration at $t = 0$ and represent the mean \pm SE. C, sorafenib plasma concentrations in mice pretreated with oral neomycin (200 mg/kg) given twice daily for 5 days. On the day of blood sample collection, SG (10 mg/kg) was administered orally. Sorafenib was not detected in plasma until 8 hours after administration of SG. All animals were female FVB mice. Data represent the mean \pm SE.




Figure 6.

Hepatocyte hopping and recirculation of SG. After oral administration, sorafenib enters the hepatocytes by incompletely defined transporters mechanisms, including OATP1B-type carriers and OCT1, and undergoes CYP3A4-mediated metabolism to sorafenib-N-oxide (s-N-oxide) and conjugation by UGT1A9 to form SG. After conjugation, SG is extensively secreted into the bile by a process that is mainly mediated by ABCC2. Under physiologic conditions, a fraction of the intracellular SG is secreted by ABCC3 and at least one other transporter back to the blood, from where it can be taken up again into downstream hepatocytes via OATP1B-type carriers (Oatp1a and Oatp1b in mice). This secretion-and-reuptake loop may prevent the saturation of ABCC2-mediated biliary excretion in the upstream hepatocytes, thereby ensuring efficient biliary elimination and hepatocyte detoxification. Once secreted into bile, SG enters the intestinal lumen where it serves as a substrate for as yet unknown bacterial β -glucuronidases (β GLU) that produce sorafenib, which subsequently undergoes intestinal absorption and reenters the systemic circulation.

drug levels in plasma following sorafenib administration (Fig. 2 and Supplementary Figs. S3 and S5). Nonetheless, these results illustrate the principle that SG biliary excretion followed by intestinal de-glucuronidation may contribute to extended maintenance of sorafenib plasma exposure in humans, and are consistent with the recent observation that neomycin treatment in humans decreased systemic exposure to sorafenib by more than 50% (32). In follow-up studies, it will be of interest, based on a physiologically based pharmacokinetic model for sorafenib, to confirm this concept in Oatp1a/1b- and Abcc2-deficient mice using repeat dosing regimens.

In conclusion, this study shows that a sinusoidal liver-to-blood shuttling loop for SG is formed by Oatp1a/1b, Abcc3, and likely another sinusoidal efflux transporter. Thus, in addition to endobiotic glucuronide metabolites like BG, xenobiotics that undergo hepatic glucuronidation can also be subject to the same hepatocyte hopping process, depending on the relative affinity of these compounds for sinusoidal and canalicular efflux transporters,

such as Abcc2 (Fig. 6). Given the broad substrate specificity of these transporters, we expect that our findings will have relevance for many other xenobiotic glucuronides. These findings also suggest that factors that interfere with the hepatocellular shuttling, biliary excretion, and/or intestinal deconjugation of SG will have a major impact on sorafenib systemic exposure and likely contribute to the substantial interindividual pharmacokinetic variability observed with sorafenib and other tyrosine kinase inhibitors undergoing glucuronidation and enterohepatic recirculation, such as regorafenib (33).

Disclosure of Potential Conflicts of Interest

S. Mani is a consultant/advisory board member for Symberix. A.H. Schinkel reports receiving other commercial research support for the Schinkel laboratory from commercial distribution of some of the mouse strains used in this study. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Authors' Contributions

Conception and design: S. Durmus, S. Mani, A. Sparreboom, S.D. Baker, A.H. Schinkel

Development of methodology: A. Vasilyeva, E. Wagenaar, S. Hu, A.A. Gibson, S.D. Baker

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Vasilyeva, S. Durmus, L. Li, E. Wagenaar, S. Hu, A.A. Gibson, S.D. Baker

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Vasilyeva, S. Durmus, S. Hu, A.A. Gibson, J.C. Panetta, S. Mani, A. Sparreboom, S.D. Baker, A.H. Schinkel

Writing, review, and/or revision of the manuscript: A. Vasilyeva, S. Durmus, S. Hu, A.A. Gibson, J.C. Panetta, S. Mani, A. Sparreboom, S.D. Baker, A.H. Schinkel

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E. Wagenaar, S. Hu, A.A. Gibson, J.C. Panetta, S. Mani

Study supervision: S.D. Baker, A.H. Schinkel

Other (idea generation): S. Mani

Acknowledgments

The authors thank Dr. John D. Schuetz for providing the C57BL/6 Abcc4^{-/-} mice.

Grant Support

This work was supported, in part, by the American Lebanese Syrian Associated Charities (ALSAC), USPHS Cancer Center Support Grant 3P30CA021765 (S.D. Baker), and NCI Grants 5R01CA138744 (S.D. Baker) and 1R01CA161879 (S. Mani).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 27, 2015; revised April 13, 2015; accepted April 24, 2015; published OnlineFirst May 7, 2015.

References

- Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. *Nat Rev Endocrinol* 2011;7:617-24.
- Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, et al. Targeted therapies and complete responses in first line treatment of

metastatic renal cell carcinoma. A meta-analysis of published trials. *Cancer Treat Rev* 2014;40:271-5.

- Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. *Crit Rev Oncol Hematol* 2014;91:1-8.

4. Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. *J Clin Oncol* 2011;29:3293–300.
5. Smolle E, Taucher V, Petru E, Haybaeck J. Targeted treatment of ovarian cancer—the multiple-kinase-inhibitor sorafenib as a potential option. *Anticancer Res* 2014;34:1519–30.
6. Drenberg CD, Baker SD, Sparreboom A. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors. *Clin Pharmacol Ther* 2013;93:215–9.
7. Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, et al. Exposure–toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. *Clin Pharmacokinet* 2014; 53:185–96.
8. Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, et al. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. *Biochem Pharmacol* 2012;84: 215–23.
9. Zimmermann EI, Roberts JL, Li L, Finkelstein D, Gibson AA, Chaudhry AS, et al. Ontogeny and sorafenib metabolism. *Clin Cancer Res* 2012; 18:5788–95.
10. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. *Clin Cancer Res* 2012;18:2099–107.
11. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. *Cancer Treat Rev* 2009;35:692–706.
12. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. *Clin Pharmacokinet* 2002;41:751–90.
13. Swift B, Nebot N, Lee JK, Han T, Proctor WR, Thakker DR, et al. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. *Drug Metab Dispos* 2013;41: 1179–86.
14. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummur S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. *Br J Clin Pharmacol* 2011;72:294–305.
15. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. *Clin Cancer Res* 2013;19:1458–66.
16. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. *J Clin Invest* 2012;122:519–28.
17. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. *J Clin Invest* 2010;120:2942–52.
18. Iusuf D, van de Steeg E, Schinkel AH. Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. *Clin Pharmacol Ther* 2012;92:559–62.
19. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. *Curr Pharm Des* 2014; 20:793–807.
20. Li L, Zhao M, Navid F, Pratz K, Smith BD, Rudek MA, et al. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010;878:3033–8.
21. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. *J Clin Oncol* 2005; 23:965–72.
22. Hing JP, Woolfrey SG, Greenslade D, Wright PM. Is mixed effects modeling or naive pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data? *J Pharmacokinet Pharmacodynam* 2001;28:193–210.
23. Liles JH, Flecknell PA. The influence of buprenorphine or bupivacaine on the post-operative effects of laparotomy and bile-duct ligation in rats. *Lab Anim* 1993;27:374–80.
24. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. *Xenobiotica* 2000;30:943–53.
25. Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, et al. Inhibition of OCTN2-mediated transport of carnitine by etoposide. *Mol Cancer Ther* 2012;11:921–9.
26. Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, et al. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. *Biol Pharm Bull* 2011;34:433–5.
27. Cui Y, König J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCB2. *Mol Pharmacol* 2001;60:934–43.
28. Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. *Drug Metab Dispos* 2014;42:561–5.
29. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. *Cancer Chemother Pharmacol* 2006;57:685–92.
30. Mani S, Boelsterli UA, Redinbo MR. Understanding and modulating mammalian-microbial communication for improved human health. *Annu Rev Pharmacol Toxicol* 2014;54:559–80.
31. Kinouchi T, Kataoka K, Miyanishi K, Akimoto S, Ohnishi Y. Biological activities of the intestinal microflora in mice treated with antibiotics or untreated and the effects of the microflora on absorption and metabolic activation of orally administered glutathione conjugates of K-region epoxides of 1-nitropyrene. *Carcinogenesis* 1993;14:869–74.
32. Nexavar package insert; Available from: http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Section 7.0, Drug Interactions, p. 14, 2013.
33. Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. *Expert Opin Drug Metab Toxicol* 2015;25:1–10.